RYTM Shorts Ease as Analysts Line Up Behind Japan Approval

RYTM sits at the lower end of short crowding among its closest rare-disease peers, even as the stock outpaced most of them this week. Short interest on Rhythm Pharmaceuticals is 15.9% of the free float, down roughly 2.5% on the week and pulling back from a one-month high near 16.6% reached in mid-October. Peers DNLI and AVTX both gained around 3% on the week, while RYTM added 4.1%, closing at $90.20. URGN was the notable laggard, dropping 8.5% over the same period.

The borrow market on RYTM is anything but stressed. Availability has expanded sharply, with roughly 44.5 million shares still available to lend against a current short position of around 10.6 million, giving an availability ratio of 1,230%. That compares with a five-week low of 627% hit on October 14, when short interest was closer to its recent peak. Since then, both the short position and borrow demand have retreated together, and the cost to borrow has eased back to 0.41% annually, near its lowest level of the past 30 days. Options positioning has edged more defensive than usual: the put/call ratio is at 0.55, nearly two standard deviations above its 20-day average of 0.50, though still well below its 52-week high of 0.64. That combination, rising availability and modest put demand, reads as cautious positioning rather than an aggressive short thesis.

Analyst coverage tells a firmly bullish story. All 12 active ratings are buys or equivalents, and the mean price target of $144 implies roughly 60% upside from current levels. JP Morgan trimmed its target modestly to $145 from $146 last week while keeping its Overweight rating, a rounding-error adjustment that changes little. More notable was William Blair initiating at Outperform on October 16, adding another name to an already crowded bull camp. HC Wainwright lifted its target to $130 from $105 on October 12, citing the Japan approval of IMCIVREE for acquired hypothalamic obesity, a market the company estimates at 5,000 to 8,000 patients. RBC Capital raised its target to $159 from $155 earlier in October and remains among the more bullish voices on the Street. Deutsche Bank is the lone hold, initiating in late August with a $120 target. The forward EPS estimate trend ranks in the 97th percentile across the ORTEX universe, the strongest factor score in the snapshot, while the analyst recommendation differential ranks in the 92nd percentile, reflecting how one-sided the Street has become.

The ORTEX short score sits at 66.4, down from a recent intra-month high of 69.3 on October 14. That drift lower tracks the easing short interest: fewer shares borrowed, more available, lower cost. The ORTEX Alt Data layer picks up one relevant reading worth noting. Medicaid dollars reimbursed for RYTM's drugs were up 20% on Q1 last year for the period ending January 2026, with Medicaid prescription volumes up 17% over the same comparison. These figures cover Q1 2026 and are sourced from the Centers for Medicare and Medicaid Services. Neither dataset has been measured to lead the company's reported figures, so they describe reimbursement trends rather than pointing to the November 3 earnings print. Wikipedia and ORTEX page-view attention is running at a z-score of 5.4 versus the company's own 90-day history, a significant spike in retail interest that arrived alongside this week's price gain.

Institutional ownership adds further context. T. Rowe Price added 911,000 shares in Q3, a meaningful addition, while JP Morgan Asset Management added over 1 million shares in the same period. RA Capital Management remains the largest disclosed holder at 9.7% of shares. No Schedule 13D activist is on the register. The most recent insider activity, CEO David Meeker exercising options and selling shares in mid-September under a pre-arranged 10b5-1 plan, was a mechanical transaction rather than a discretionary signal. The prior earnings print, reported August 4, produced a 7.7% one-day gain and a 9.8% five-day gain, the only data point in the history. Q3 results are scheduled for November 3, thirteen days away.

The level to watch is whether short interest continues its two-week decline toward the September base of roughly 10 million shares, or whether new bearish positioning rebuilds ahead of the Q3 print and its first read on the Japan commercial launch.